Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1955 1
1956 1
1960 8
1961 16
1962 21
1963 24
1964 26
1965 20
1966 11
1967 19
1968 16
1969 14
1970 9
1971 18
1972 16
1973 5
1974 10
1975 10
1976 8
1977 9
1978 13
1979 4
1980 3
1981 8
1982 3
1983 7
1984 4
1985 5
1986 9
1987 6
1988 5
1989 3
1990 8
1991 11
1992 3
1993 6
1994 8
1995 3
1996 8
1997 4
1998 5
1999 8
2000 25
2001 49
2002 71
2003 77
2004 100
2005 103
2006 135
2007 120
2008 121
2009 107
2010 119
2011 122
2012 96
2013 112
2014 114
2015 102
2016 99
2017 98
2018 100
2019 108
2020 125
2021 139
2022 133
2023 135
2024 138
2025 155
2026 82

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,978 results

Results by year

Filters applied: . Clear all
Page 1
Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.
Lim AWY, Schneider L, Loy C. Lim AWY, et al. Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD001747. doi: 10.1002/14651858.CD001747.pub4. Cochrane Database Syst Rev. 2024. PMID: 39498781 Free PMC article.
We judged four studies to be at high risk of bias due to attrition and two due to selective outcome reporting. Galantamine for dementia due to Alzheimer's disease We summarise only the results for galantamine given at 8 to 12 mg twice daily (total galantamine …
We judged four studies to be at high risk of bias due to attrition and two due to selective outcome reporting. Galantamine for dement …
Galantamine beyond Alzheimer's disease-a fact or artefact?
Naguy A, Husain K, Alamiri B. Naguy A, et al. CNS Spectr. 2022 Jun;27(3):268-271. doi: 10.1017/S1092852920002229. Epub 2020 Dec 14. CNS Spectr. 2022. PMID: 33308343 Review.
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. ...
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer's disease. ...
Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond.
Koola MM. Koola MM. Psychiatry Res. 2020 Nov;293:113409. doi: 10.1016/j.psychres.2020.113409. Epub 2020 Aug 18. Psychiatry Res. 2020. PMID: 32829072 Review.
Despite the major unmet clinical need, no new medications for the treatment of AD have been approved since 2003. Galantamine is an acetylcholinesterase inhibitor that is also a positive allosteric modulator at the alpha4beta2 and alpha7nACh receptors. Memantine is an N-met …
Despite the major unmet clinical need, no new medications for the treatment of AD have been approved since 2003. Galantamine is an ac …
Galantamine in Alzheimer's disease.
Razay G, Wilcock GK. Razay G, et al. Expert Rev Neurother. 2008 Jan;8(1):9-17. doi: 10.1586/14737175.8.1.9. Expert Rev Neurother. 2008. PMID: 18088197 Review.
Galantamine has a large volume clearance, low plasma protein binding and a high bioavailability. ...Adverse events experienced by patients treated with galantamine are usually mild, gastrointestinal and may improve with dose reduction....
Galantamine has a large volume clearance, low plasma protein binding and a high bioavailability. ...Adverse events experienced by pat …
Galantamine ameliorates experimental pancreatitis.
Thompson DA, Tsaava T, Rishi A, George SJ, Hepler TD, Hide D, Pavlov VA, Brines M, Chavan SS, Tracey KJ. Thompson DA, et al. Mol Med. 2023 Oct 31;29(1):149. doi: 10.1186/s10020-023-00746-y. Mol Med. 2023. PMID: 37907853 Free PMC article.
Activating the CAP ameliorates experimental acute pancreatitis. Galantamine is an acetylcholinesterase inhibitor (AChEI) which amplifies the CAP via modulation of central muscarinic ACh receptors (mAChRs). However, as mAChRs also activate pancreatitis, it is currently unkn …
Activating the CAP ameliorates experimental acute pancreatitis. Galantamine is an acetylcholinesterase inhibitor (AChEI) which amplif …
Galantamine for vascular cognitive impairment.
Birks J, Craig D. Birks J, et al. Cochrane Database Syst Rev. 2006 Jan 25;(4):CD004746. doi: 10.1002/14651858.CD004746.pub2. Cochrane Database Syst Rev. 2006. PMID: 23862185
Statistically significant benefits favouring galantamine over placebo in assessments of cognition (ADAS-cog, MD -1.50, 95% CI -2.39 to -0.61, P = 0.0009), and favouring placebo compared with galantamine for behaviour (NPI, MD 1.80, 95% CI0.29 to 3.31, P = 0.02) are …
Statistically significant benefits favouring galantamine over placebo in assessments of cognition (ADAS-cog, MD -1.50, 95% CI -2.39 t …
Galantamine for vascular cognitive impairment.
Craig D, Birks J. Craig D, et al. Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD004746. doi: 10.1002/14651858.CD004746.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2006 Jan 25;(4):CD004746. doi: 10.1002/14651858.CD004746.pub2. PMID: 16437493 Free PMC article. Updated.
OBJECTIVES: To assess the efficacy of galantamine in the treatment of people with vascular cognitive impairment or vascular dementia or "mixed" dementia. ...In the galantamine treated group, significantly higher numbers of patients dropped out and withdrew due to an …
OBJECTIVES: To assess the efficacy of galantamine in the treatment of people with vascular cognitive impairment or vascular dementia …
Galantamine for Alzheimer's disease.
Olin J, Schneider L. Olin J, et al. Cochrane Database Syst Rev. 2001;(1):CD001747. doi: 10.1002/14651858.CD001747. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2001;(4):CD001747. doi: 10.1002/14651858.CD001747. PMID: 11279727 Updated.
BACKGROUND: Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) can be isolated from several plants, including daffodil bulbs, and now synthesized. ...Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, …
BACKGROUND: Galantamine (also called galanthamine, marketed as Reminyl (Janssen)) can be isolated from several plants, including daff …
Galantamine for Alzheimer's disease.
Olin J, Schneider L. Olin J, et al. Cochrane Database Syst Rev. 2002;(3):CD001747. doi: 10.1002/14651858.CD001747. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001747. doi: 10.1002/14651858.CD001747.pub2. PMID: 12137632 Updated.
Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastrointestinal symptoms acutely and with dosage increases. ...Galantamine's safety profile is similar to that of other cholinesteras …
Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastroin …
Galantamine for Alzheimer's disease.
Olin J, Schneider L. Olin J, et al. Cochrane Database Syst Rev. 2001;(4):CD001747. doi: 10.1002/14651858.CD001747. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747. doi: 10.1002/14651858.CD001747. PMID: 11687119 Updated.
Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastrointestinal effects acutely and with dosage increases. ...Galantamine's safety profile is similar to other cholinesterase inhibit …
Galantamine's adverse effects appear similar to those of other cholinesterase inhibitors, in that it tends to produce gastroin …
2,978 results